RGNX

NASDAQ open

REGENXBIO

7.27 USD
▲+0.09+1.25%
盘后 7.24 0.00%
2026-11-20
市值
$473.44M
市盈率
—
EPS
-3.15
股息率
—
52 周区间
5.46 – 16.19
成交量
521.45K
Beta
1.23
目标价
21.40
52W 低 5.4652W 高 16.19
价格走势

公司简介

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-12...

关联新闻